Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 4(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00032929Phase 3Completed

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

Role: collaborator

NCT00531947Phase 4Completed

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

Role: lead

NCT00285766Phase 3Completed

Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

Role: lead

NCT00531596Phase 4Completed

Evaluation of Adhesion and Dermal Tolerability of EMSAM

Role: lead

NCT00532116Phase 4Completed

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

Role: lead

All 5 trials loaded